Cargando…

Evaluation of GATA3 and GCDFP15 Expression in Triple Negative Breast Cancers

BACKGROUND & OBJECTIVE: Breast cancer is one of the most common cancers in the world. There are some different types of breast cancer and triple-negative breast cancer is the type in which no receptors for estrogen, progesterone, and human epidermal growth factor receptor-2 are expressed. Identi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahadi, Mahsa, Moradi, Afshin, Rabiee, Elham, Pourmotahari, Fatemeh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Iranian Society of Pathology 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10293598/
https://www.ncbi.nlm.nih.gov/pubmed/37383162
http://dx.doi.org/10.30699/IJP.2023.561917.2969
_version_ 1785063022898708480
author Ahadi, Mahsa
Moradi, Afshin
Rabiee, Elham
Pourmotahari, Fatemeh
author_facet Ahadi, Mahsa
Moradi, Afshin
Rabiee, Elham
Pourmotahari, Fatemeh
author_sort Ahadi, Mahsa
collection PubMed
description BACKGROUND & OBJECTIVE: Breast cancer is one of the most common cancers in the world. There are some different types of breast cancer and triple-negative breast cancer is the type in which no receptors for estrogen, progesterone, and human epidermal growth factor receptor-2 are expressed. Identifying factors that can facilitate the diagnosis of triple-negative breast cancer is important. In this study, we decided to investigate the expression of GATA3 and GCDFP15 genes in triple-negative breast cancers. METHODS: This is a retrospective descriptive-analytical study that was performed on 50 specimens of samples of triple-negative breast cancer. Data including age and sex, tumor grade, tumor size, types of invasion, GATA-3, and GCDFP-15 were assessed. RESULTS: The mean age of the patients was 48.3±14.17 years. Of the total specimens, 46% were positive for GCDFP15 and 90% were positive for GATA-3. The intensity of GATA3 was evaluated and it was observed that 33(73.3%) of the cells were strongly stained and 12(26.7%) were weakly stained. There were no relationships between GATA-3 and GCDFP-15 with tumor characteristics. CONCLUSION: GATA-3 and GCDFP-15 may serve as diagnostic markers for triple-negative breast cancers and GATA-3 seems to be more reliable.
format Online
Article
Text
id pubmed-10293598
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Iranian Society of Pathology
record_format MEDLINE/PubMed
spelling pubmed-102935982023-06-28 Evaluation of GATA3 and GCDFP15 Expression in Triple Negative Breast Cancers Ahadi, Mahsa Moradi, Afshin Rabiee, Elham Pourmotahari, Fatemeh Iran J Pathol Original Article BACKGROUND & OBJECTIVE: Breast cancer is one of the most common cancers in the world. There are some different types of breast cancer and triple-negative breast cancer is the type in which no receptors for estrogen, progesterone, and human epidermal growth factor receptor-2 are expressed. Identifying factors that can facilitate the diagnosis of triple-negative breast cancer is important. In this study, we decided to investigate the expression of GATA3 and GCDFP15 genes in triple-negative breast cancers. METHODS: This is a retrospective descriptive-analytical study that was performed on 50 specimens of samples of triple-negative breast cancer. Data including age and sex, tumor grade, tumor size, types of invasion, GATA-3, and GCDFP-15 were assessed. RESULTS: The mean age of the patients was 48.3±14.17 years. Of the total specimens, 46% were positive for GCDFP15 and 90% were positive for GATA-3. The intensity of GATA3 was evaluated and it was observed that 33(73.3%) of the cells were strongly stained and 12(26.7%) were weakly stained. There were no relationships between GATA-3 and GCDFP-15 with tumor characteristics. CONCLUSION: GATA-3 and GCDFP-15 may serve as diagnostic markers for triple-negative breast cancers and GATA-3 seems to be more reliable. Iranian Society of Pathology 2023 2023-03-23 /pmc/articles/PMC10293598/ /pubmed/37383162 http://dx.doi.org/10.30699/IJP.2023.561917.2969 Text en https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution- 4.0 International License (https://creativecommons.org/licenses/by/4.0/) which permits Share, copy and redistribution of the material in any medium or format or adapt, remix, transform, and build upon the material for any purpose, even commercially.
spellingShingle Original Article
Ahadi, Mahsa
Moradi, Afshin
Rabiee, Elham
Pourmotahari, Fatemeh
Evaluation of GATA3 and GCDFP15 Expression in Triple Negative Breast Cancers
title Evaluation of GATA3 and GCDFP15 Expression in Triple Negative Breast Cancers
title_full Evaluation of GATA3 and GCDFP15 Expression in Triple Negative Breast Cancers
title_fullStr Evaluation of GATA3 and GCDFP15 Expression in Triple Negative Breast Cancers
title_full_unstemmed Evaluation of GATA3 and GCDFP15 Expression in Triple Negative Breast Cancers
title_short Evaluation of GATA3 and GCDFP15 Expression in Triple Negative Breast Cancers
title_sort evaluation of gata3 and gcdfp15 expression in triple negative breast cancers
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10293598/
https://www.ncbi.nlm.nih.gov/pubmed/37383162
http://dx.doi.org/10.30699/IJP.2023.561917.2969
work_keys_str_mv AT ahadimahsa evaluationofgata3andgcdfp15expressionintriplenegativebreastcancers
AT moradiafshin evaluationofgata3andgcdfp15expressionintriplenegativebreastcancers
AT rabieeelham evaluationofgata3andgcdfp15expressionintriplenegativebreastcancers
AT pourmotaharifatemeh evaluationofgata3andgcdfp15expressionintriplenegativebreastcancers